PRME — Prime Medicine, Inc. stock price, charts and financials

Latest market price

2.98

+0.17+6.05%

Overview Short InterestFilings

PRMEQT13Prime Medicine, Inc.·NASDAQ

Overview Short InterestFilings

2.98+6.05%

Loading chart...

Signal & projected range

Short-squeeze setupHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

OCUL+2.26%$8.59 MESO+2.28%$14.80 AUPH+2.47%$14.93 TYRA+1.53%$32.53 URGN+3.45%$39.92 IOVA+0.93%$4.36 STOK+7.14%$31.67 TSHA+7.27%$6.20

Snapshot

Index	-	P/E	-	EPS (ttm)	-1.27	Insider Own	39.72%	Shs Outstand	180.62M	Perf Week	-3.56%

Market Cap	538.24M	Forward P/E	-	EPS next Y	-0.88	Insider Trans	0.00%	Shs Float	59.17M	Perf Month	-25.31%

Enterprise Value	509.24M	PEG	-	EPS next Q	-	Inst Own	-	Short Float	56.68%	Perf Quarter	-14.12%

Income	-199.00M	P/S	134.56	EPS this Y	21.50%	Inst Trans	-	Short Ratio	10.82	Perf Half Y	-21.58%

Sales	4.00M	P/B	6.99	EPS next Y	11.80%	ROA	-67.31%	Short Interest	33.54M	Perf YTD	-14.12%

Book/sh	0.43	P/C	3.99	EPS next 5Y	-	ROE	-188.82%	52W High	6.94 -57.06%	Perf Year	-26.24%

Cash/sh	0.75	P/FCF	-	EPS past 3/5Y	-	ROIC	-77.39%	52W Low	2.67 11.61%	Perf 3Y	-79.92%

Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- 0.00%	Gross Margin	-1082.70%	Volatility	5.33% 6.79%	Perf 5Y	-

Dividend TTM	-	EV/Sales	127.31	EPS Y/Y TTM	23.10%	Oper. Margin	-5121.77%	ATR (14)	0.24	Perf 10Y	-

Dividend Ex-Date	Mar 22, 2018	Quick Ratio	3.80	Sales Y/Y TTM	33.33%	Profit Margin	-4917.55%	RSI (14)	42.98	Recom	2.33

Dividend Gr. 3/5Y	-	Current Ratio	3.80	EPS Q/Q	30.00%	SMA20	-9.01%	Beta	2.34	Target Price	7.00

Payout	0.00%	Debt/Eq	0.89	Sales Q/Q	0.00%	SMA50	-9.02%	Rel Volume	0.93	Prev Close	2.81

Employees	146	LT Debt/Eq	0.89	Earnings	Aug 06	SMA200	-19.14%	Avg Volume	3.37M	Price	2.98

IPO Date	Oct 20, 2022	Option/Short	No / Yes	EPS/Sales Surpr.	-11.59% -63.24%	Net Debt/EBITDA	-0.26	Volume	3,146,577	Change	6.05%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Jun-29-26	Reiterated	New Street		$8.00
Jun-29-26	Upgrade	HC Wainwright & Co.	Neutral → Buy
Jun-22-26	Reiterated	Goldman Sachs		$6.00
May-27-25	Downgrade	Citigroup	Buy → Neutral
May-20-25	Downgrade	HC Wainwright & Co.	Buy → Neutral
May-20-25	Downgrade	JP Morgan	Overweight → Neutral
May-16-24	Upgrade	Citigroup	Neutral → Buy
May-07-24	Reiterated	Jefferies
Apr-02-24	Initiated	Wedbush	Buy
Oct-09-23	Reiterated	BMO Capital

Latest News

Jul-30-26

Jul-30-2611:06AM

Prime Medicine, Inc. (PRME) May Report Negative Earnings: Know the Trend Ahead of Q2 Releasezacks.com

Jul-23-26

Jul-23-2604:15PM

Prime Medicine Says FDA Clears IND Application For PM577a, Investigational In Vivo Prime Editor For Wilson Disease; Initial Clinical Data Expected In 2027Benzinga

04:05PM

Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM577a in H1069Q-mutated Wilson Diseaseglobenewswire.com

Jul-21-26

Jul-21-2603:16AM

Prime Medicine, Inc. $PRME Shares Sold by Amova Asset Management Americas Inc.defenseworld.net

Jul-09-26

Jul-09-2610:22AM

Prime Medicine Beats Beam Therapeutics In Patent Dispute - But Both Are Investableseekingalpha.com

Jul-08-26

Jul-08-2601:29PM

Prime Medicine Secures Favorable Arbitration Ruling in Beam Therapeutics CaseBenzinga

08:00AM

Prime Medicine Announces Positive Resolution to Arbitration with Beam Therapeuticsglobenewswire.com

Jun-29-26

Jun-29-2609:58AM

Iridium Communications, FuelCell Energy, Rocket Lab And Other Big Stocks Moving Higher On MondayBenzinga

Jun-26-26

Jun-26-2608:40AM

Beam Therapeutics: A Better Entry Point Is Likely Coming (Rating Downgrade)SeekingAlpha

Jun-22-26

Jun-22-2608:14AM

Prime Medicine Says FDA Grants Regenerative Medicine Advanced Therapy Designation To PM359, Investigational Autologous Prime Edited Hematopoietic Stem Cell Therapy For Treatment Of p47phox-deficient CGDBenzinga

Jun-18-26

Jun-18-2608:08AM

Prime Medicine Receives New Zealand's Regulator Clearance For Its Clinical Trial Application For PM577a To Treat Wilson DiseaseBenzinga

Jun-13-26

Jun-13-2604:51AM

Prime Medicine's Prime Editing Is Worth The RiskSeekingAlpha

Company

Prime Medicine, Inc. operates as a biotechnology firm, dedicated to delivering genetic therapies for various diseases by strategically employing advanced gene editing technology. Central to their platform is the "Prime Editor" system, which combines a unique Prime Editor protein—a hybrid composed of a Cas protein and a reverse transcriptase enzyme—with a specialized pegRNA molecule. This pegRNA plays a crucial role by both guiding the Prime Editor to a precise location within the genome and providing the essential template for introducing the desired modification to the target DNA sequence. The company, founded in 2019, maintains its headquarters in Cambridge, Massachusetts.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019
Total Revenue	4	5	3	0	0	0	5	0
Cost of Goods Sold Incl. D&A	48	7	0	0	0	0	3	3
Gross Profit	-44	-3	3	0	0	0	2	-3
Selling, General and Administrative Excl. Other	56	52	50	43	30	14	3	1
Research and Development	154	161	155	148	87	71	3	1
Other Operating Expense	-47	-7	0	14	0	-1	-3	0
Operating Income	-207	-208	-202	-205	-117	-84	-1	-2
Interest Expense	0	0	0	0	0	0	0	0
Unusual Expense	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	9	7	7	6	-6	-81	-1	0
Net Income Before Taxes	-199	-201	-196	-198	-123	-166	-2	-3
Income Taxes	0	0	0	0	-1	0	2	0
Consolidated Net Income	-199	-201	-196	-198	-122	-165	-3	-3
Net Income From Continuing Operations	-199	-201	-196	-198	-122	-165	-3	-3
Net Income	-199	-201	-196	-198	-122	-165	-3	-3
EPS (Recurring)	-1.27	-1.35	-1.65	-2.18	-1.46	-1.92	-0.05	-0.03
EPS (Basic, Before Extraordinaries)	-1.27	-1.35	-1.65	-2.18	-1.46	-1.92	-0.05	-0.03
EPS (Diluted)	-1.27	-1.35	-1.65	-2.18	-1.46	-1.92	-0.05	-0.03
EBITDA	-191	-196	-190	-187	-121	-165	-1	-2
Other After Tax Adjustments	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—
Price To Earnings Ratio	—	—	—	—	—	—	—	—
Price To Sales Ratio	131.87	103.41	115.83	—	—	—	—	—
Gross Margin	-1,100.00	-60.00	100.00	—	—	—	40.00	—
Operating Margin	-5,175.00	-4,160.00	-6,733.33	—	—	—	-20.00	—
Net Margin	-4,975.00	-4,020.00	-6,533.33	—	—	—	-60.00	—
Shares Outstanding	177	149	119	91	97	96	96	96
Market Capitalization	527	517	347	806	1,802	—	—	—
Operating Lease Expense	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
GV 2021 GP, L.L.C.	10% Owner	Aug 01 '25	Buy	3.30	1,500,000	4,950,000	3,262,440	Aug 05
ARCH Venture Partners X, LLC	10% Owner	Aug 01 '25	Buy	3.30	3,030,300	9,999,990	6,230,300	Aug 01
NELSEN ROBERT	director, 10 percent owner:	Aug 01 '25	Buy	3.30	3,030,300	9,999,990	6,230,300	Aug 01
ARCH Venture Partners XII, LLC	10% Owner	Aug 01 '25	Buy	3.30	3,030,300	9,999,990	6,230,300	Aug 01
Liu David R.	10% Owner	Jun 30 '25	Buy	2.52	21,000	52,830	20,240,945	Jul 01
Liu David R.	10% Owner	Jun 23 '25	Buy	2.16	21,000	45,402	20,219,945	Jun 23
Liu David R.	10% Owner	Jun 16 '25	Buy	1.49	21,000	31,196	20,198,945	Jun 16
Liu David R.	10% Owner	Jun 11 '25	Buy	1.60	21,000	33,590	20,177,945	Jun 12
LEE ANN L.	Chief Technical Officer	May 21 '25	Buy	1.13	100,000	113,000	100,000	May 22
Reine Allan	Chief Executive Officer	May 21 '25	Buy	1.18	125,000	147,150	125,000	May 22
Brudnick Richard	Chief Business Officer	May 20 '25	Buy	1.19	20,000	23,790	20,000	May 22
NELSEN ROBERT	director, 10 percent owner:	Feb 15 '24	Buy	6.25	3,200,000	20,000,000	3,200,000	Feb 20
ARCH Venture Partners XII, LLC	10% Owner	Feb 15 '24	Buy	6.25	3,200,000	20,000,000	3,200,000	Feb 20
ARCH Venture Partners X, LLC	10% Owner	Feb 15 '24	Buy	6.25	3,200,000	20,000,000	3,200,000	Feb 20
GV 2019 GP, L.L.C.	10% Owner	Jun 21 '23	Sale	14.97	19,003	284,496	0	Jun 22

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.